US FDA approves Lantheus' new prostate cancer imaging formulation

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through increased production capacity. Shares of the company were up about 4% in extended trading. The imaging agent, Pylarify, targets prostate-specific membrane antigen (PSMA), a